Q-line Biotech
Spreading Healthiness!

To,
The Listing Department
National Stock Exchange of India Limited,
"Exchange Plaza" 5th Floor, Plot No. C-1, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai – 400051

Date: 26-11-2026

NSE Symbol: QLINE ISIN-INE1G2W01011

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements Regulations), 2015 – Update

Ref: Intimation dated November 12, 2026.

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), and in continuation of our earlier intimation dated November 12, 2026, the Company has successfully completed the acquisition of (70% paid up share capital) of Heidelco Medicore Private Limited. Accordingly, Heidelco Medicore Private Limited has become a subsidiary of the Company with effect from November 26, 2026.

Details pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 has already been disclosed on 12th November 2026 to the exchange.

Thanking You,

For Q-Line Biotech Limited

SAURABH GARG
Digitally signed by SAURABH GARG
Date: 2026.11.26 17:27:46 +05'30'

Saurabh Garg
Managing Director
DIN- 02891621
Place: Lucknow